Amilcar Torres Figueroa, MD
Internal Medicine · San Juan, PRNPI 1093782500
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 27.5% of the total. Reporting peaked in 2021 at $1,159 and has fallen 64.7% since, to $409 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- PBG Puerto Rico LLC$767
- Boehringer Ingelheim$673
- Sanofi-aventis U.S. LLC$595
- E.r. Squibb & Sons, L.L.C.$486
- Johnson & Johnson$378
- plus $1K from 11 others
What the payments were for
- Food & beverage$6,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 89 | $1,651 |
| PBG Puerto Rico LLC | 38 | $767 |
| Boehringer Ingelheim | 27 | $673 |
| Sanofi-aventis U.S. LLC | 29 | $595 |
| E.r. Squibb & Sons, L.L.C. | 21 | $486 |
| Johnson & Johnson | 17 | $378 |
| GSK | 15 | $346 |
| Merck | 17 | $299 |
| Eli Lilly Export S.A. Puerto Rico Branch | 9 | $190 |
| Novo Nordisk | 8 | $166 |
| Pfizer | 5 | $116 |
| AbbVie(2 entities) | 4 | $100 |
| Pfizer Pharmaceuticals LLC | 4 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| Amgen | 2 | $45 |
| Exact Sciences | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
How this compares
$6,014 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 199 | $155,391 |
| JardianceEmpagliflozin | 103 | $79,281 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 95 | $78,965 |
| EliquisApixaban | 105 | $74,729 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 76 | $62,082 |
| SynthroidLevothyroxine Sodium | 441 | $45,032 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $35,383 |
| XareltoRivaroxaban | 49 | $32,192 |
| Xigduo XrDapaglifloz Propaned/Metformin | 45 | $31,598 |
| TrulicityDulaglutide | 25 | $27,571 |
| PrezcobixDarunavir/Cobicistat | 11 | $27,471 |
| TivicayDolutegravir Sodium | 12 | $27,421 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,691 |
| OzempicSemaglutide | 24 | $23,446 |
| ProliaDenosumab | 12 | $21,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Glyxambi, Synjardy | $673 | $261,048341 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $1,651 | $169,782236 claims |
| PfizerEliquis | $116 | $74,729105 claims |
| AbbVieSynthroid, Lumigan, Savella | $100 | $70,709506 claims |
| Johnson & JohnsonXarelto, Prezcobix | $378 | $59,66360 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $595 | $42,995118 claims |
| MerckJanuvia, Janumet Xr | $299 | $32,96542 claims |
| GSKTrelegy Ellipta | $346 | $23,69136 claims |
| Novo NordiskOzempic | $166 | $23,44624 claims |
| AmgenProlia | $45 | $21,02212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in San Juan
- Ricardo FernandezSan Juan$351K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
- Natalia Almodovar ArbeloSan Juan$9K
- Jeremy FelicianoSan Juan$8K
- Porfirio Diaz-RodriguezSan Juan$8K
- Pedro del Valle de TomasSan Juan$7K
- Rafael Figueroa NavarroSan Juan$6K
- Hector Leon-FigueroaSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.